TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma

Stopped The Sponsor made the decision to close enrollment as part of a strategic portfolio review.

Conditions

• Head and Neck Neoplasms

Interventions

• DRUG: TransCon TLR7/8 Agonist
• DRUG: Pembrolizumab
• DRUG: TransCon IL-2 β/γ

Sponsor

Ascendis Pharma A/S